Alterity Therapeutics Ltd (ATHE) stock has gained 11.45% in the pre-market on Tuesday, March 15, 2020, as of this writing. Yesterday ATHE stock lost 3.49% and closed at $1.66 per share.
Recent ATHE Activities
- Participation in the Global Life Science Conference
Alterity Therapeutics participated in the HC Wainwright Global Life Science Conference, and the CEO of the company Dr Stamler represented the company and gave a presentation to the investors virtually.
His presentation focused on
- The progress of the ATHE lead compound ATH434 for the treatment of Multiple System Atrophy (MSA);
- Expanded safety data on ATH434;
- Update on a Natural History Study in MSA at Vanderbilt University Medical Center in the US, which is providing essential data to inform and de-risk the phase 2 clinical study;
- The expected commercialization pathway for ATH434 including the initiation of Phase 2 clinical trial; and
- The underlying science.
- Participation in 7th International Congress of Multiple System Atrophy
ATHE participated in a virtual format at the 7th International Congress of Multiple System Atrophy (MSA2021), held between February 26-27, 2021.
The event was a world-leading conference on Multiple System Atrophy (MSA), and the presentation was featured as part of the Congress’ poster presentations. It is available online, and access is only on demand.
- 2ndGrant from The Michael J. Fox Foundation
On February 9, 2021, ATHE confirmed the 2ndgrant from The Michael J. Fox Foundation for Parkinson’s research. The US$495,000 funding will be used to determine the optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease based on imaging of brain iron.
Alterity Therapeutics was founded in Melbourne, Australia, in 1997 as Prana Biotechnology. The company has offices in Melbourne, Australia, and San Francisco, USA. ATHE lead candidate, ATH434 (formerly PBT434), is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by redistributing labile iron in the brain. In this way, it can treat Parkinson’s disease and atypical forms of Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).